Published in Infect Immun on September 01, 1984
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun (1988) 2.63
Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev (1992) 2.60
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J Bacteriol (1986) 2.00
Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun (1987) 1.97
Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine (2010) 1.60
Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med (2006) 1.36
Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09
Preferential use of DH reading frame 2 alters B cell development and antigen-specific antibody production. J Immunol (2008) 1.04
Genetic control of DH reading frame and its effect on B-cell development and antigen-specifc antibody production. Crit Rev Immunol (2010) 1.02
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
Polyspecific human and murine antibodies to diphtheria and tetanus toxoids and phospholipids. Clin Exp Immunol (1988) 0.96
Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines. Vaccine (2015) 0.95
Back to the future: recombinant polyclonal antibody therapeutics. Curr Opin Chem Eng (2013) 0.86
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med (2013) 0.84
Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Mol Pharm (2011) 0.84
Antibodies against the light chain of tetanus toxin in human sera. Infect Immun (1985) 0.84
Characterisation of a panel of anti-tetanus toxin single-chain Fvs reveals cooperative binding. Mol Immunol (2010) 0.82
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs. Toxins (Basel) (2015) 0.79
Expression of tetanus toxin subfragments in vitro and characterization of epitopes. Infect Immun (1989) 0.78
Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS One (2014) 0.76
Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA. PLoS One (2017) 0.75
Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display Library. Toxins (Basel) (2016) 0.75
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry (1978) 22.56
Tetanus toxin. Microbiol Rev (1979) 2.25
Isolation and purification of two antigenically active, "complimentary" polypeptide fragments of tetanus neurotoxin. Infect Immun (1975) 1.74
Monoclonal antibodies as probes of tetanus toxin structure and function. Infect Immun (1983) 1.34
An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. J Neurochem (1977) 1.26
Production and characterization of monoclonal antibodies to tetanus toxin. Infect Immun (1984) 1.17
Antigenic substructure of tetanus neurotoxin. Biochem Biophys Res Commun (1977) 1.15
Papain-derived fragment IIc of tetanus toxin: its binding to isolated synaptic membranes and retrograde axonal transport. Brain Res (1981) 1.07
Structure of tetanus toxin: the arrangement of papain digestion products within the heavy chain-light chain framework of extracellular toxin. Biochim Biophys Acta (1981) 1.05
Studies on tetanus antitoxins. II. Demonstration of at least four antitoxins of different specificity in antitoxic sera. J Immunol (1973) 1.03
A review of the molecular structure of tetanus toxin. Mol Cell Biochem (1982) 1.02
Tetanus neurotoxin. Rev Physiol Biochem Pharmacol (1982) 1.01
Monoclonal antibodies against tetanus toxin and toxoid. Med Microbiol Immunol (1983) 0.95
Use of the B-IIb tetanus toxin derived fragment as a specific neuropharmacological transport agent. Brain Res (1980) 0.94
Requirement of at least two distinct monoclonal antibodies for efficient neutralization of tetanus toxin in vivo. Naturwissenschaften (1982) 0.93
Preparation of conjugates using two tetanus toxin derived fragments: their binding to gangliosides and isolated synaptic membranes and their immunological properties. Toxicon (1980) 0.87
Antigenic determinants of the HLA-B7 molecule; Bw6- and B7-specific determinants are spatially separate. Immunogenetics (1983) 0.84
Replacement of the international standard for tetanus antitoxin and the use of the standard in the flocculation test. Bull World Health Organ (1970) 0.84
[Heterogeneity of tetanus anatoxin]. Ann Inst Pasteur (Paris) (1971) 0.81
Comparative sedimentation coefficients of RNA extracted from plaque-forming and defective particles of vesicular stomatitis virus. J Mol Biol (1966) 6.61
Defective T particles of vesicular stomatitis virus. I. Preparation, morphology, and some biologic properties. Virology (1966) 6.37
Dissociation and reconstitution of the transcriptase and template activities of vesicular stomatitis B and T virions. J Virol (1972) 5.93
Classification of rhabdovirus proteins: a proposal. J Virol (1972) 5.54
Proteins of vesicular stomatitis virus: kinetics and cellular sites of synthesis. J Virol (1970) 4.85
Structural proteins of vesicular stomatitis viruses. J Virol (1969) 4.70
Protein composition of the structural components of vesicular stomatitis virus. J Virol (1969) 4.54
The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J Virol (1972) 4.04
Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol (1979) 3.54
Defective T particles of vesicular stomatitis virus. II. Biologic role in homologous interference. Virology (1966) 3.49
L protein requirement for in vitro RNA synthesis by vesicular stomatitis virus. J Virol (1973) 3.26
Lipid composition of purified vesicular stomatitis viruses. J Virol (1971) 3.25
Spatial relationships of the proteins of vesicular stomatitis virus: induction of reversible oligomers by cleavable protein cross-linkers and oxidation. J Virol (1977) 2.77
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Carbohydrate composition of vesicular stomatitis virus. J Virol (1971) 2.40
Cytoplasmic compartmentalization of the protein and ribonucleic acid species of vesicular stomatitis virus. J Virol (1972) 2.37
Inhibition of cellular RNA synthesis by nonreplicating vesicular stomatitis virus. Proc Natl Acad Sci U S A (1965) 2.37
Tetanus toxin. Microbiol Rev (1979) 2.25
Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1995) 2.23
Protein kinase and phosphoproteins of vesicular stomatitis virus. J Virol (1974) 2.11
Temperature-sensitive mutants of vesicular stomatitis virus: synthesis of virus-specific proteins. J Virol (1971) 2.05
Viral liposomes released from insect cells infected with recombinant baculovirus expressing the matrix protein of vesicular stomatitis virus. J Virol (1993) 2.02
Functional and antigenic domains of the matrix (M1) protein of influenza A virus. J Virol (1987) 1.98
Characterisation of Tn1721, a new transposon containing tetracycline resistance genes capable of amplification. Mol Gen Genet (1979) 1.95
Localization of membrane-associated proteins in vesicular stomatitis virus by use of hydrophobic membrane probes and cross-linking reagents. J Virol (1980) 1.89
Association of vesicular stomatitis virus glycoprotein with virion membrane: characterization of the lipophilic tail fragment. J Virol (1975) 1.88
Adjuvants--a balance between toxicity and adjuvanticity. Vaccine (1993) 1.86
Ribonucleic acid species of intracellular nucleocapsids and released virions of vesicular stomatitis virus. J Virol (1972) 1.86
Mapping regions of the matrix protein of vesicular stomatitis virus which bind to ribonucleocapsids, liposomes, and monoclonal antibodies. J Virol (1986) 1.78
Restitution of infectivity to spikeless vesicular stomatitis virus by solubilized viral components. J Virol (1975) 1.77
Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol (1989) 1.73
Role of matrix protein in assembling the membrane of vesicular stomatitis virus: reconstitution of matrix protein with negatively charged phospholipid vesicles. Biochemistry (1981) 1.71
Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A (1998) 1.68
Inhibition of RNA and interferon synthesis in Krebs-2 cells infected with vesicular stomatitis virus. Virology (1966) 1.67
Regulation of viral transcription by the matrix protein of vesicular stomatitis virus probed by monoclonal antibodies and temperature-sensitive mutants. J Virol (1985) 1.66
Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol (1999) 1.65
Sialoglycoprotein of vesicular stomatitis virus: role of the neuraminic acid in infection. J Virol (1974) 1.63
Action of interferon: kinetics and differential effects on viral functions. J Virol (1970) 1.63
The plus-strand leader RNA of VSV inhibits DNA-dependent transcription of adenovirus and SV40 genes in a soluble whole-cell extract. Cell (1982) 1.61
Glycoprotein biosynthesis. Incorporation of glycosyl groups into endogenous acceptors in a Golgi apparatus-rich fraction of liver. J Biol Chem (1971) 1.60
Location of the transcription defect in group I temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1974) 1.58
C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A (1998) 1.57
Mosquito cells infected with vesicular stomatitis virus yield unsialylated virions of low infectivity. J Virol (1975) 1.57
Differential inhibition of host protein synthesis in L cells infected with RNA - temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1976) 1.55
Enveloped viruses as model membrane systems: microviscosity of vesicular stomatitis virus and host cell membranes. Biochemistry (1976) 1.54
Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J Virol (1982) 1.54
Inhibition of RNA synthesis in mouse myeloma cells infected with vesicular stomatitis virus. J Virol (1978) 1.51
Reconstitution into liposomes of the glycoprotein of vesicular stomatitis virus by detergent dialysis. J Biol Chem (1979) 1.48
Nucleus-targeting domain of the matrix protein (M1) of influenza virus. J Virol (1995) 1.46
Reversible inhibition of interferon synthesis by puromycin: evidence for an interferon-specific messenger RNA. Proc Natl Acad Sci U S A (1965) 1.44
RNA- temperature-sensitive mutants of vesicular stomatitis virus: L-protein thermosensitivity accounts for transcriptase restriction of group I mutants. J Virol (1976) 1.44
Use of UV irradiation to identify the genetic information of vesicular stomatitis virus responsible for shutting off cellular RNA synthesis. J Virol (1979) 1.44
Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue. J Virol (1994) 1.42
Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A (2000) 1.42
Membrane-binding domains and cytopathogenesis of the matrix protein of vesicular stomatitis virus. J Virol (1994) 1.39
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol (1999) 1.38
Structural proteins of two salmonid rhabdoviruses. J Virol (1975) 1.36
Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors. J Virol (1988) 1.33
Classification of the New Jersey serotype of vesicular stomatitis virus into two subtypes. J Virol (1978) 1.32
Enzymatic transfer of 14C-glucosamine from UDP-N-acetyl-14C-glucosamine to endogenous acceptors in a Golgi apparatus-rich fraction from liver. Biochem Biophys Res Commun (1969) 1.32
Monoclonal antibodies to the M protein of vesicular stomatitis virus (Indiana serotype) and to a cDNA M gene expression product. J Virol (1985) 1.28
Inhibition of viral transcriptase by immunoglobulin directed against the nucleocapsid NS protein of vesicular stomatitis virus. J Virol (1975) 1.27
An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. J Neurochem (1977) 1.26
Influence of the peripheral matrix protein of vesicular stomatitis virus on the membrane dynamics of mixed phospholipid vesicles: fluorescence studies. Biochemistry (1983) 1.23
Inhibition of transcription by immunoglobulins directed against the ribonucleoprotein of homotypic and heterotypic vesicular stomatitis viruses. J Virol (1978) 1.22
Inhibition by aurintricarboxylic acid and polyethylene sulfonate of RNA transcription of vesicular stomatitis virus. J Virol (1975) 1.21
Microviscosity of togavirus membranes studied by fluorescence depolarization: influence of envelope proteins and the host cell. J Virol (1976) 1.21
The occurrence of 4-amino-4-deoxy-L-arabinose as a constituent in Salmonella lipopolysaccharide preparations. Eur J Biochem (1970) 1.20
Transcription of vesicular stomatitis virus is required to shut off cellular RNA synthesis. J Virol (1979) 1.20
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.20
Cellular adsorption function of the sialoglycoprotein of vesicular stomatitis virus and its neuraminic acid. J Virol (1975) 1.19
Nature, type of linkage, and absolute configuration of (hydroxy) fatty acids in lipopolysaccharides from Xanthomonas sinensis and related strains. J Bacteriol (1975) 1.16
Rabbit macrophage interferons. II. Some physicochemical properties and estimations of molecular weights. J Exp Med (1967) 1.16
Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). Biomed Pharmacother (1998) 1.16
Use of antiviral-antiferritin hybrid antibody for localization of viral antigen in plasma membrane. J Virol (1971) 1.15
Antigenicity, function, and conformation of synthetic oligopeptides corresponding to amino-terminal sequences of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1988) 1.14
Comparative inhibition of cellular transcription by vesicular stomatitis virus serotypes New Jersey and Indiana: role of each viral leader RNA. J Virol (1983) 1.13
Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus (New Jersey serotype): a method for preliminary mapping of epitopes. Virology (1987) 1.12
Viral membranes: model systems for studying biological membranes. CRC Crit Rev Biochem (1979) 1.10
Lipid organization of the membrane of vesicular stomatitis virus. J Biol Chem (1978) 1.10
Nucleotide sequence and secondary structure of VSV leader RNA and homologous DNA involved in inhibition of DNA-dependent transcription. Cell (1984) 1.10
Reversal by certain polyanions of an endogenous inhibitor of the vesicular stomatitis virus-associated transcriptase. J Biol Chem (1978) 1.09
Effect of phospholipase C and cholesterol oxidase on membrane integrity, microviscosity, and infectivity of vesicular stomatitis virus. Biochemistry (1977) 1.08
Isolation and identification of N-acetyl-3-amino-3,6-dideoxy-D-galactose, a cell wall constituent of Xanthomonas campestris. J Biol Chem (1965) 1.08
The incorporation of 14C-glucosamine from UDP-N-acetyl-14C-glucosamine into liver microsomal protein in vitro. Arch Biochem Biophys (1969) 1.07
Papain-derived fragment IIc of tetanus toxin: its binding to isolated synaptic membranes and retrograde axonal transport. Brain Res (1981) 1.07
Rhabdoviridae. Report of the Rhabdovirus Study Group, International Committee on Taxonomy of Viruses. Intervirology (1979) 1.07
Glycoprotein micelles isolated from vesicular stomatitis virus spontaneously partition into sonicated phosphatidylcholine vesicles. Virology (1980) 1.07
Adenosine-5'-O-(3-thiotriphosphate) as an affinity probe for studying leader RNA's transcribed by vesicular stomatitis virus. J Biol Chem (1979) 1.05